What are the symptoms and treatment options for an older adult with a family history of glaucoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Glaucoma Symptoms and Management in Older Adults with Family History

Symptoms of Glaucoma

Primary open-angle glaucoma (POAG), the most common form, is typically asymptomatic in early stages, which is why up to 75% of cases remain undiagnosed. 1, 2

Early-Stage POAG (Most Common)

  • No symptoms in the majority of patients—this is the critical pitfall that leads to delayed diagnosis 3, 4
  • Gradual peripheral vision loss that patients typically do not notice until advanced stages 2
  • Central vision remains intact until late disease 4

Acute Angle-Closure Glaucoma (Medical Emergency)

  • Sudden severe eye pain and headache 5
  • Blurred vision with halos around lights (due to corneal edema) 5
  • Eye redness 5
  • Mid-dilated, non-reactive pupil 5
  • Nausea and vomiting 5
  • This requires immediate ophthalmologic referral to prevent permanent vision loss within hours 5

Risk Assessment for Your Patient

Family history increases glaucoma risk 1.92 to 9.2-fold depending on the number of affected relatives, making this patient high-risk and qualifying them for Medicare-covered screening. 6

Additional Risk Factors to Assess

  • Age over 65 years (prevalence increases from 2.7% at age 43-49 to 7.7% at age 75-79) 1
  • African American ethnicity (3-fold higher risk) 6
  • Hispanic ethnicity (4.7% prevalence over age 40) 6
  • Type 2 diabetes mellitus 1
  • Myopia 1
  • Hypothyroidism 1
  • Low blood pressure or cardiovascular disease 1, 7

Screening and Diagnosis Recommendations

This patient should be referred to an ophthalmologist for comprehensive evaluation including tonometry, optical coherence tomography, gonioscopy, and visual field testing—not screened in primary care. 1, 6

Why Primary Care Screening is Inadequate

  • Hand-held tonometers and ophthalmoscopes lack acceptable diagnostic accuracy 1
  • Approximately 50% of POAG patients have intraocular pressure (IOP) below 22 mmHg at single screening, missing half of cases 1
  • Diagnosis requires monitoring over years to document progressive changes 7

Comprehensive Ophthalmologic Evaluation Should Include

  • IOP measurement via tonometry (normal is ≤21 mmHg, but not diagnostic alone) 1, 4
  • Optic nerve head examination looking for cup-to-disc ratio ≥0.3 7
  • Optical coherence tomography (OCT) to detect retinal nerve fiber layer thinning 1, 7
  • Visual field testing (perimetry) to identify characteristic peripheral defects 1, 4
  • Gonioscopy to differentiate open-angle from angle-closure glaucoma 1
  • Central corneal thickness measurement (thinner corneas increase risk) 1

Risk Calculator Utilization

Use the validated OHTS risk calculator (available at https://ohts.wustl.edu/risk/) incorporating age, cup-to-disc ratio, pattern standard deviation, central corneal thickness, and IOP to estimate 5-year risk of developing glaucoma. 1

Treatment Approach

Treatment should only be initiated when definitive glaucoma is diagnosed with documented optic nerve damage or visual field loss—not based solely on family history or elevated IOP. 6

First-Line Treatment Options

Topical prostaglandin analogs or beta-blockers are first-line medical therapy, with selective laser trabeculoplasty as an alternative primary treatment. 1, 3

Medical Therapy

  • Prostaglandin analogs (most commonly used first-line) 3, 8
  • Beta-blockers (timolol) 9, 3
    • Contraindicated in patients with asthma, COPD, sinus bradycardia, or heart block 9
  • Alpha-2 agonists (second-line adjunctive therapy) 3, 8
  • Topical carbonic anhydrase inhibitors (second-line adjunctive therapy) 3, 8
  • Oral carbonic anhydrase inhibitors (acetazolamide) for acute situations 10

Laser Therapy

  • Selective laser trabeculoplasty should be considered when medication adherence, cost, convenience, or side effects are concerns 1

Treatment Goals

The target IOP should be set at 20% below the mean of several baseline measurements, with the ultimate goal of preventing visual field loss that would affect quality of life. 1

  • Target pressure must be individualized and may require adjustment during follow-up 1
  • Medical treatment reduces visual field progression with odds ratio 0.62 compared to no treatment 6
  • Combined medical/surgical treatment reduces progression with hazard ratio 0.56 6

Surgical Options (When Medical Therapy Fails)

  • Trabeculectomy 8
  • Glaucoma drainage tube implantation 8
  • Ciliary body cyclodestruction 8

Critical Management Pitfalls

Common Errors to Avoid

  • Do not rely on IOP alone for diagnosis—50% of POAG patients have normal IOP 1, 4
  • Do not use timolol in patients with respiratory disease or cardiac conduction abnormalities 9
  • Do not treat elevated IOP without documented optic nerve or visual field damage (this is ocular hypertension, not glaucoma) 1
  • Do not assume family history alone warrants treatment—it only increases screening priority 6

Medication Adherence Barriers

  • Emphasize that glaucoma medications prevent blindness despite lack of symptoms 2
  • Address cost concerns (Medicare covers screening for high-risk patients including those with family history) 1, 6
  • Monitor for medication side effects that reduce adherence 1

Prognosis Considerations

Without treatment, POAG progresses to significant visual impairment, but with proper IOP-lowering therapy, progression can be delayed or prevented in most patients. 3, 8

  • Untreated acute angle-closure glaucoma has 18% risk of blindness within 4-10 years 5
  • African Americans with family history face particularly rapid progression 6
  • Vision loss from glaucoma is irreversible, making early detection and treatment essential 4, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Glaucoma and its treatment: a review.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005

Research

Open-angle glaucoma.

American family physician, 2003

Guideline

Acute Angle-Closure Glaucoma Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Risk of Family History in Glaucoma: Screening and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Glaucoma: Diagnosis and Management.

American family physician, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.